| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8486082 | Vaccine | 2018 | 7 Pages |
Abstract
QIV is cost-effective (payer perspective) or even cost-saving (societal perspective) in Japan.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Shinya Tsuzuki, Markus Schwehm, Martin Eichner,